The IQVIA Institute recently published a report on biopharma companies. Important findings include:
- There are nearly 4,000 products in clinical development by emerging biopharma companies, which does not include research programs where emerging biopharma companies may be partnering with larger companies.
- Since 2011, the emerging biopharma pipeline more than doubled, growing 165% with much of that growth coming in the last five years.
- The emerging biopharma R&D clinical pipeline has grown on average 18% annually over the last five years, compared to just 11% for the pipeline across all company sizes, highlighting the increasing important of emerging biopharma to the development of new therapies.
- Larger companies have seen slower growth over the last five years with large pharma averaging 2% growth annually, mid-sized companies averaging less than 1% growth annually and small companies averaging 3% growth annually.
You can read the full report here.
